United Therapeutics price target lowered to $460 from $475 at UBS
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
Patient Advocates from NCCN Guidelines Panels Share Their 'United by Unique' Stories for World Cancer Day
The National Comprehensive Cancer Network® (NCCN®) is joining people and organizations across the globe to commemorate World ...
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe ...